DR. JOHN SARANTOPOULOS, M.D.

Plain English
This study looked at a drug called zilovertamab vedotin to see if it can help people with advanced solid tumors, like certain types of breast, lung, ovarian, and pancreatic cancers, who have already been treated without success. Out of 102 participants, only 1% responded positively to the treatment, and patients lived about 2.3 months without their disease getting worse on the higher dose, and 1.9 months on the lower dose. The findings indicate that this drug doesn't have enough effectiveness for these types of cancer, meaning it likely won't be used further in these cases. Who this helps: This helps doctors and researchers understand which treatments may not be effective for patients with advanced solid tumors.

Plain English
This study tested a combination treatment of lenvatinib and eribulin in patients with hard-to-treat solid tumors like breast and lung cancer. Out of 29 patients, 24% had a positive response to the treatment, with 29% of breast cancer patients and 33% of lung cancer patients showing improvement. Patients who did not express a protein called vimentin had better outcomes, and while there were some serious side effects reported, the overall treatment was manageable. Who this helps: This helps patients with advanced solid tumors, particularly those who have already undergone multiple treatments.

Plain English
This study looked at a new treatment combining two antibodies, ieramilimab and spartalizumab, for patients with advanced cancers, like lung and breast cancer. Out of 235 patients, those who had not previously received similar treatments showed long-lasting responses for more than two years, with the most common side effects being itchiness and fatigue. This matters because it offers hope for improved treatment options for patients with hard-to-treat cancers. Who this helps: This helps patients with advanced solid tumors, especially those who haven't had prior anti-PD-1 treatments.

Plain English
This study looked at whether the drug metformin could help prevent metabolic syndrome in men undergoing androgen deprivation therapy (ADT) for advanced prostate cancer. Researchers found that after 28 weeks, there were no significant changes in weight, waist size, insulin levels, or prostate-specific antigen (PSA) levels between the men taking metformin and those taking a placebo. This matters because it suggests that metformin does not provide benefits in reducing metabolic issues related to ADT, which is important for managing patient health during cancer treatment. Who this helps: This helps patients undergoing ADT for prostate cancer.

Plain English
This study looked at a new treatment called PCA062, designed for patients with solid tumors that express a protein called P-cadherin. Researchers tested the safety and effectiveness of PCA062 in 47 patients, but found that most of them (78.7%) had to stop treatment due to their cancer worsening. Only one patient saw a partial improvement in their condition, leading Novartis to stop further development of this treatment because it didn't show enough benefit. Who this helps: This information helps patients with solid tumors, especially those hoping for new treatment options.

Plain English
This study examined a new treatment combining ieramilimab (a LAG-3 inhibitor) and spartalizumab (an anti-PD-1 antibody) for patients with advanced cancer who had not responded to other therapies. Out of 255 patients, the combination showed some effectiveness, with 2% achieving complete responses and 8% having partial responses, while most side effects were mild. The findings suggest that this combination treatment is tolerable and may provide modest benefits for certain patients. Who this helps: This helps cancer patients who have not had success with existing treatments.

Plain English
Researchers studied a new treatment combination of ARRY-382 and pembrolizumab in patients with advanced solid tumors. They found that while the treatment was generally safe, with 10.5% of patients showing some improvement in their cancer, only a few had significant responses that lasted for months. This matters because it helps us understand the potential of combining these therapies, even if the benefits were limited. Who this helps: This helps patients with advanced cancers like pancreatic and ovarian cancer who may be looking for new treatment options.

Plain English
This study looked at the drug lurbinectedin, which was tested on 28 adults with relapsed Ewing sarcoma, a type of bone cancer. The results showed that 14.3% of patients responded to the treatment, with the effects lasting about 4.2 months. On average, patients lived for 12 months after starting the treatment, and most side effects were manageable. Who this helps: This research benefits patients with relapsed Ewing sarcoma by offering a potential new treatment option.

Plain English
This study looked at how combining two drugs, vorinostat and hydroxychloroquine, compares to regorafenib in treating patients with metastatic colorectal cancer that hasn’t responded to other treatments. The results showed that patients taking vorinostat and hydroxychloroquine had a median progression-free survival of 1.9 months, while those on regorafenib had 4.35 months, indicating that regorafenib was more effective. However, both treatments were well tolerated, and patients showed signs of improved immune response against tumors, highlighting potential benefits of the combination treatment in certain patients. Who this helps: This helps patients with advanced colorectal cancer who are seeking new treatment options.

Plain English
This study looked at how the drug sonidegib affects the levels of two other drugs, warfarin and bupropion, in cancer patients receiving treatment. Researchers found that taking 800 mg of sonidegib daily did not significantly change how the body processes warfarin or bupropion, meaning there were only small effects on their levels in the blood. This matters because it shows that sonidegib can be safely used alongside these medications without interfering with their effectiveness. Who this helps: This benefits patients with advanced solid tumors who are also taking warfarin or bupropion.

Plain English
This study looked at two experimental cancer treatments, sabatolimab and spartalizumab, in patients with advanced solid tumors, including ovarian and colorectal cancers. Of the 219 patients involved, sabatolimab alone did not show any positive responses, but when combined with spartalizumab, 6% of patients experienced a reduction in tumor size, lasting between 12 to 27 months. The trial found that the combination was generally safe, with fatigue being the most common side effect, affecting 15% of those receiving both treatments. Who this helps: This research benefits cancer patients looking for new treatment options, especially those with advanced solid tumors.

Plain English
This study looked at a new drug called M2698 in patients with advanced cancer who had not responded to standard treatments. Out of 101 patients treated with M2698, about 27% experienced stable disease after 12 weeks, and two patients with breast cancer even showed signs of tumor shrinkage, with progression-free survival lasting up to 31 months. This research is important because it shows that M2698 can be a potential option for patients whose cancer has become resistant to existing therapies. Who this helps: This helps patients with advanced cancer, particularly those with treatment-resistant conditions.

Plain English
This study tested a new drug called citarinostat combined with the standard chemotherapy drug paclitaxel in patients with advanced cancers that had previously been treated. Out of 20 patients, 3 had a partial response to the treatment, and 13 had stable disease, which means their cancer did not worsen. The combination was found to be safe, with no serious side effects at the tested doses, and the recommended dose for future use is 360 mg of citarinostat daily. Who this helps: This benefits patients with advanced solid tumors who have not responded to other treatments.

Plain English
This study tested a new drug called imalumab on patients with advanced cancer to see how safe it is and how well it works. The researchers found that the highest dose that patients could tolerate was 37.5 mg every two weeks, and at this dose, 13 out of 39 patients had no worsening of their disease for at least four months. This matters because it shows that imalumab can be safely administered and may help some patients manage their cancer better. Who this helps: This helps patients with advanced solid tumors and their doctors in evaluating new treatment options.

Plain English
This study looked at a new drug called lurbinectedin as a second-line treatment for patients with small-cell lung cancer (SCLC) who did not respond to their first treatment. Out of 105 patients treated, about 35% (37 patients) showed a positive response to the drug. Although there were some serious side effects, like low white blood cell counts, no one died from the treatment, indicating that lurbinectedin may be a valuable option for patients who have limited choices after their initial therapy fails. Who this helps: This helps patients with small-cell lung cancer who need new treatment options after their first therapy.

Plain English
Researchers studied the effectiveness of a drug called lurbinectedin in patients with small cell lung cancer (SCLC) who had a break of at least 180 days from their last chemotherapy treatment. They found that 60% of the 20 patients responded to the treatment, with the benefits lasting an average of 5.5 months, and most patients (95%) had their disease controlled. Additionally, 61% were alive after one year, which shows that lurbinectedin could be a useful alternative to reusing the first treatment. Who this helps: This helps patients with small cell lung cancer who have already had previous treatments and are looking for new options.

Plain English
This study tested a new drug called LYC-55716 (cintirorgon) to see if it is safe and how well it can help patients with certain difficult-to-treat cancers. Researchers found that among 32 patients, the drug was mostly safe to use, with mild side effects like diarrhea and fatigue. Notably, two patients experienced a reduction in their tumors, and eleven others had their disease stabilize for up to 12 months. This is important because it shows that LYC-55716 may be a promising new treatment option for patients with advanced cancers. Who this helps: This helps patients with relapsed or refractory metastatic cancers.

Plain English
This study looked at how well the cancer drug osimertinib is processed in patients with mild or moderate liver problems compared to those with normal liver function. It found that drug levels in the blood were lower by 51% and 61% for patients with mild and moderate liver issues, respectively, but overall, patients still had enough drug exposure to effectively treat their cancer. Importantly, no changes to the drug's dosage are needed for these patients, and the safety of the drug remained the same across all groups. Who this helps: This helps cancer patients with mild or moderate liver impairment.

Plain English
This study looked at how well the drug alisertib is processed in adults with advanced cancer who have varying levels of liver function, specifically comparing those with normal, moderate, and severe liver impairment. It found that patients with moderate or severe liver issues had about 150% higher levels of the active form of the drug in their bloodstream compared to those with normal liver function. This is important because it suggests that patients with liver problems need a lower dose of alisertib to avoid potential side effects while still getting effective treatment. Who this helps: This helps patients with cancer who have liver dysfunction, ensuring they receive safer and more effective treatment.

Plain English
This study looked at a new treatment called mipsagargin for adults with advanced liver cancer who did not respond to or could not tolerate a previous treatment called sorafenib. Out of 25 patients, none showed improvement in their tumors, but 63% had stable disease for a period of time, with patients living an average of about 205 days after starting treatment. Mipsagargin appears to be relatively safe and may help stabilize the disease by reducing blood flow to the tumors. Who this helps: This benefits patients with advanced liver cancer who have not found success with other treatments.

Plain English
This study looked at the effects of combining two cancer drugs, alpelisib and infigratinib, in patients with specific genetic mutations (PIK3CA) and possible alterations in growth factor receptors (FGFR). Researchers found that while the two drugs could be given at their full doses, 71% of patients had to stop treatment or reduce their dosage due to side effects. This matters because it helps understand how to treat cancers with these mutations, though the combination didn’t show strong additional benefits in patients with both types of alterations. Who this helps: Patients with PIK3CA-mutant cancers and their doctors.

Plain English
This study looked at how the drug alisertib affects the heart's electrical activity in patients with serious cancers. Researchers found that taking alisertib, even at the highest recommended dose of 50 mg twice a day, did not significantly change the heart's QT interval, which measures the time it takes for the heart to recharge after beating. This is important because it means alisertib is safe for heart function at this dosage. Who this helps: This benefits patients being treated for advanced cancers.

Plain English
This research studied how certain medications affect the levels of alisertib, a drug being tested for treating advanced cancers. They found that using esomeprazole increased alisertib's levels in the body by 28%, while rifampin decreased its levels by 47%. This matters because combining these drugs with alisertib can change how the cancer treatment works, potentially making it less effective or more harmful. Who this helps: Patients receiving alisertib for advanced cancers.

Plain English
This study looked at how high doses of a drug called dabrafenib, used to treat certain tumors, affected heart rhythm in patients. They found that taking 300 mg of dabrafenib twice a day did not significantly change the heart’s QTc interval, which is important for heart health; the average increase was only 2.86 milliseconds, well within safe limits. This is important because it shows that patients can take this medication at a higher dose without major heart-related side effects. Who this helps: This helps patients with BRAF V600-mutant tumors and their doctors.

Plain English
This study looked at how liver problems affect the way the drug crizotinib works and its safety in patients with advanced cancer. The results showed that patients with normal liver function had a higher concentration of the drug in their system compared to those with liver impairments. For patients with mild liver issues, the standard dose remains the same, but those with moderate liver issues should get a lower dose, while patients with severe liver problems should take even less. Who this helps: This research benefits cancer patients with liver impairments receiving crizotinib.

Plain English
This study looked at how safe and effective a drug called cabazitaxel is for cancer patients with liver problems. Researchers found that while patients with mild or moderate liver impairment could safely take cabazitaxel at reduced doses of 20 mg/m² and 15 mg/m², those with severe liver impairment faced too many side effects, leading to the study's early halt. This information is crucial because it helps doctors make informed decisions about using cabazitaxel in patients with different levels of liver health, ensuring better care and safety. Who this helps: This helps doctors and patients dealing with cancer and liver impairment.

Plain English
This study looked at the drug REOLYSIN (pelareorep) combined with carboplatin and paclitaxel to treat patients with advanced malignant melanoma, a serious type of skin cancer. Out of 14 patients, 21% had a partial response to the treatment, with manageable side effects like fever and fatigue. The study found that patients lived a median of about 11 months after treatment, with a one-year survival rate of 43%. Who this helps: This research benefits patients with advanced melanoma seeking new treatment options.

Plain English
This study looked at what makes cancer treatment programs at top academic centers successful, focusing on 16 different centers across the U.S. It found that the most successful programs had strong support from donors, experienced staff, and a focus on basic research and patient communication. The key factors included things like reducing bureaucratic delays and having a diverse group of cancer trials available. Who this helps: This helps patients seeking access to new cancer treatments and the doctors who care for them.

Plain English
This study evaluated the safety and effectiveness of a drug called dinaciclib in patients with advanced cancers. After testing several doses, the researchers found that three different infusion schedules (2 hours, 8 hours, and 24 hours) were tolerable, with dose-limiting side effects such as low blood cell counts and fever. Although no patients showed significant tumor shrinkage, eight patients experienced stable disease for up to 30 treatment cycles, indicating that the drug may help some patients manage their cancer. Who this helps: This benefits cancer patients who are looking for new treatment options.

Plain English
This study looked at how the drug carfilzomib behaves in the body of patients with different levels of liver function, particularly those with advanced cancers. Researchers found that patients with mild and moderate liver issues had carfilzomib levels in their bodies that were, on average, about 20-50% higher than those with normal liver function. However, these differences are not considered to be clinically important given the natural variability in how the drug is processed. Who this helps: Patients with advanced cancers who have liver impairment could benefit from this research.

Plain English
This study looked at 170 cancer patients with liver problems to see if including those with severe liver dysfunction in early drug trials makes sense. It found that patients with severe liver dysfunction survived for only one month on average, compared to two months for the whole group; better survival was linked to better liver function and higher albumin levels. This matters because it highlights the need for better criteria, like albumin levels, to choose the right patients for these trials, ensuring that research is both safe and useful. Who this helps: Patients with liver dysfunction and those involved in clinical trials.

Plain English
This study tested a new cancer drug called pevonedistat in patients with advanced solid tumors to find the highest safe dose and check how the drug affects the body and the tumors. Researchers found that the maximum tolerated dose was between 50 mg/m² and 67 mg/m², and 74% of patients experienced stable disease, meaning their tumors did not grow. These results are important because they show that pevonedistat can be safely given at these doses, suggesting it could be a potential treatment for certain cancers. Who this helps: This research benefits cancer patients, especially those with advanced solid tumors.

Plain English
This study looked at a new cancer treatment called KHK2866, which is designed to target a specific growth factor linked to cancer. In total, 20 patients received various doses of the drug, and while it generally lowered certain cancer-related markers in the blood, some patients experienced serious side effects like seizures and confusion, leading to the trial being stopped. Ultimately, the findings highlight both the potential of KHK2866 to affect cancer biology and the risk it poses for neurological issues, emphasizing the need for caution in using this treatment. Who this helps: This helps patients with advanced cancer by advancing understanding of potential new treatments.

Plain English
This study looked at how eating affects the way the drug alisertib is absorbed in the body for patients with advanced solid tumors. Researchers found that the drug's absorption was similar whether patients had fasted or eaten a high-fat meal beforehand, with only slight differences in levels of the drug in the blood (84% absorption when fed compared to fasting). These findings suggest that patients can take alisertib without worrying about eating beforehand, making it easier for them to manage their treatment. Who this helps: This helps patients taking alisertib by simplifying their medication routine.

Plain English
In this study, researchers tested a new cancer treatment combining alisertib and docetaxel to see if it was safe and effective for patients with advanced solid tumors. They found that the best dosage to use was 20 mg of alisertib taken twice a day for a week, along with docetaxel at 75 mg/m² given once every 21 days. Out of the patients evaluated, 29% showed tumor shrinkage, including one patient with bladder cancer who had a complete response. Who this helps: This research benefits cancer patients looking for new treatment options, particularly those with hard-to-treat tumors.

Plain English
This study evaluated the combination of two drugs, vorinostat (VOR) and hydroxychloroquine (HCQ), in patients with advanced colorectal cancer that hasn't responded to other treatments. In a group of 20 patients, the average time without cancer progression was about 2.8 months, and the average overall survival time was 6.7 months. The treatment showed signs of enhancing the immune response to tumors while also inhibiting a cell process called autophagy, which might contribute to cancer growth. Who this helps: This benefits patients with advanced colorectal cancer who have not responded to existing therapies.

Plain English
This study looked at how safe and effective the drug pralatrexate is for patients with advanced solid tumors and lymphoma who have different levels of kidney function. Out of 29 enrolled patients, 27 received at least one dose of pralatrexate. The findings showed that patients with mild or moderate kidney issues could take the usual dose of 30 mg without problems, while those with severe kidney impairment should only take 15 mg to avoid higher toxicity risks. Who this helps: This research benefits patients with cancer and kidney impairment.

Plain English
This study looked at whether the capsule and tablet forms of a cancer drug called dovitinib (TKI258) produce the same effects in patients with advanced solid tumors, excluding breast cancer. Researchers found that both forms were essentially equivalent, meaning they worked similarly in the body, as shown by the exposure levels being very close (with ratios of 0.95 and 0.98). This matters because it confirms that patients can use either form without worrying about different outcomes or effects. Who this helps: Patients with advanced solid tumors who need treatment with dovitinib.

Plain English
This study looked at the effectiveness of combining a drug called BNC105P with everolimus to treat advanced kidney cancer. Researchers found that 6 months without the disease getting worse was similar for both the combination treatment (33.8%) and everolimus alone (30.3%), showing no significant advantage for adding BNC105P. It matters because while the treatment didn't improve survival as hoped, the study identified potential biomarkers that could help in future research. Who this helps: This helps researchers looking for better treatment options for advanced kidney cancer patients.

Plain English
This study looked at a new liquid version of a cancer drug called alisertib to see how well it works compared to its capsule form in patients with advanced tumors. Researchers found that the liquid version was 26% more absorbed in the body than the capsule version and acted faster, with patients reaching peak drug levels in one hour instead of two. This is important because it could provide a better treatment option for patients who have difficulty swallowing pills. Who this helps: Patients with advanced solid tumors who struggle with swallowing pills.

Plain English
This study looked at how well the cancer drug eribulin mesylate is processed in the bodies of patients with different levels of kidney function. It found that patients with moderate renal impairment needed lower doses (1.1 mg/m²) to have similar drug exposure as those with normal kidney function who received the standard dose of 1.4 mg/m². This matters because it helps ensure that patients with kidney issues can still receive effective treatment without experiencing unnecessary side effects. Who this helps: Patients with moderate to severe kidney impairment undergoing cancer treatment.

Plain English
This study looked at how effective treatments that inhibit VEGF (a protein that helps tumors grow) are for patients with metastatic colorectal cancer (mCRC). Researchers found that while VEGF inhibitors like bevacizumab can delay the progression of the disease (with improvements seen in 3-4 months of progression-free survival), they do not significantly extend overall survival compared to other types of treatments. This is important because it raises questions about whether these treatments should still be used in later stages of cancer when better options may exist. Who this helps: This information is useful for doctors treating patients with metastatic colorectal cancer.

Plain English
This study looked at a treatment for advanced melanoma using two drugs: sorafenib and bevacizumab, which aim to block tumor growth by stopping blood vessel formation. Out of 14 patients treated, none showed tumor reduction, but 57% had stable disease for at least 16 weeks, with three patients maintaining stability for over a year, and the average time before their condition worsened was 32 weeks. Some patients experienced side effects, like high blood pressure and fatigue, but those with lower levels of a protein related to blood vessel growth had better outcomes, staying stable for about 50 weeks compared to only 15 weeks in those with higher levels. Who this helps: This research benefits patients with advanced melanoma by potentially guiding future treatment options based on their VEGF levels.

Plain English
Researchers studied a combination treatment of hydroxychloroquine (HCQ) and vorinostat (VOR) in 27 patients with advanced solid tumors to see if it was safe and effective. They found that the maximum safe doses were 600 mg of HCQ and 400 mg of VOR, with some patients experiencing mild side effects like nausea and fatigue, while one patient showed a positive response to the treatment, and two had stable disease for a longer period. This combination treatment might offer a new way to enhance cancer therapies using HDAC inhibitors. Who this helps: This benefits cancer patients, particularly those with advanced solid tumors.

Plain English
This study looked at how a combination of two cancer drugs, cabazitaxel and cisplatin, works in patients with advanced solid tumors. Researchers found that the best tolerated dose was cabazitaxel at 15 mg/m2 and cisplatin at 75 mg/m2 given every three weeks, with 67% of patients showing stable disease. These findings are important because they suggest that the combination treatment is both safe and potentially effective, indicating it may be worth investigating further in more targeted studies. Who this helps: Patients with advanced solid tumors.

Plain English
This study looked at early-stage clinical trials (Phase I) of cancer drugs to see which factors might predict if a drug would eventually gain approval from the FDA. The researchers analyzed data from 88 cancer drugs tested between 2000 and 2013, finding that drugs showing a better response rate — with 423 people having complete responses and 342 showing partial responses — were more likely to be approved. The findings suggest that how well a drug performs in these early trials can indicate its chances of later approval, which is important because it could help streamline the drug development process. Who this helps: This benefits patients and doctors by potentially speeding up access to effective cancer treatments.

Plain English
This study tested a new cancer treatment called ATI-1123, which delivers a drug called docetaxel in a way that might lower side effects. Out of 29 patients with advanced solid tumors, the maximum safe dose was found to be 90 mg/m², with some patients experiencing moderate side effects like fatigue and nausea. At this dose, one patient showed a partial response to the treatment, and 75% had stable disease, which means their tumors didn't get worse. Who this helps: This research benefits cancer patients seeking new treatment options.

Plain English
This study looked at how different medications affect the levels of cabazitaxel, a cancer treatment drug, in patients with advanced solid tumors. Researchers found that taking the drug ketoconazole decreased cabazitaxel clearance by 20%, while rifampin increased it by 21%. This matters because using drugs that strongly influence how cabazitaxel is processed in the body can alter its effectiveness and safety, so these combinations should be avoided. Who this helps: This benefits cancer patients who may be prescribed cabazitaxel as part of their treatment.